Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 4/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1634220 | 0.77 | CYP1A2 (0.41) | L3MBTL1 | |
| SCHEMBL1492586 | 0.76 | CA1 (0.32) | — | |
| SCHEMBL1635096 | 0.75 | TSHR (0.34) | CHRM2SMN1; SMN2L3MBTL1CYP2D6 | |
| SCHEMBL1634610 | 0.74 | SMN1; SMN2 (0.43) | AHRCHRM2SMN1; SMN2L3MBTL1CETP | |
| SCHEMBL13936214 | 0.72 | SMN1; SMN2 (0.40) | AHRCHRM2SMN1; SMN2L3MBTL1BLM | |
| SCHEMBL1492580 | 0.72 | NR3C1 (0.35) | — | |
| SCHEMBL22090291 | 0.71 | LTA4H (0.43) | SMN1; SMN2 | |
| SCHEMBL12705444 | 0.71 | SMN1; SMN2 (0.45) | CHRM2SMN1; SMN2L3MBTL1BLMCYP2D6 | |
| SCHEMBL28012581 | 0.71 | SLC6A3 (0.37) | CHRM2SMN1; SMN2CYP2D6 | |
| SCHEMBL30001155 | 0.67 | SMN1; SMN2 (0.38) | AHRCHRM2SMN1; SMN2L3MBTL1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8212040-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8212040-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-7932392-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932392-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7553966-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553966-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1490062-B1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMA (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20060189647-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20050282881-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| US-6903215-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-20050059714-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| EP-1490062-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040023999-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003082280-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189647-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and thereof | NR3C1, NR3C2, MC2R | AHR 637/4885CHRM2 402/4885SMN1; SMN2 2664/4885 |
| US-20050059714-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | AHR 644/4885CHRM2 309/4885SMN1; SMN2 2771/4885 |
| US-20040023999-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | AHR 817/4885CHRM2 1053/4885SMN1; SMN2 2745/4885 |
| US-20050282881-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | AHR 708/4885CHRM2 294/4885SMN1; SMN2 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.